Physician profile
Sneha Bency
NPI 1316698814
$1,489.54
in general payments reported to CMS, 2019-2025
19 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $26.64 · 2024: $463 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,482 · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,482.02 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $267.59 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $250.63 | 2024-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $188.43 | 2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $167.23 | 2024-2025 | Qelbree |
| Tg Therapeutics, INC. | $125.00 | 2025 | |
| Axsome Therapeutics, INC. | $76.95 | 2025 | Auvelity |
| Abbvie INC. | $60.87 | 2025 | |
| Neurocrine Biosciences, INC. | $54.62 | 2024 | Ingrezza |
| Lundbeck LLC | $52.04 | 2024-2025 | Rexulti, Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $50.10 | 2025 | Hyqvia |
| Merck Sharp & Dohme LLC | $26.64 | 2023 | Vaxneuvance, Proquad, M-M-R II |
| Genzyme Corporation | $26.36 | 2025 | |
| Corium, LLC | $25.94 | 2024 | Azstarys |
| Genentech USA, INC. | $25.01 | 2025 | Ocrevus Zunovo |
| Collegium Pharmaceutical, INC. | $23.78 | 2025 | Jornay Pm |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $19.11 | 2025 | Austedo Xr |
| Argenx US, INC. | $18.43 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Alkermes, INC. | $16.94 | 2024 | Lybalvi |
| Sage Therapeutics, LLC | $13.87 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sneha Bency listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.